Researchers are excitedly examining retatrutide, a innovative drug from Eli Lilly, as a significant step in body management. Different than many earlier approaches, retatrutide is a dual -action receptor targeting both GLP-1 and GIP, hormones that affect appetite and blood glucose control . Preli